Israel Englander Uni Qure N.V. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Uni Qure N.V. stock. As of the latest transaction made, Millennium Management LLC holds 2,189,981 shares of QURE stock, worth $15.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,189,981

Previous 515,221 325.06%

Holding current value

$15.6 Million

Previous $2.31 Million 367.76%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.78 - $10.12 $6.33 Million - $16.9 Million	1,674,760 Added 325.06%	2,189,981 $10.8 Million
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $178,418 - $220,686	40,642 Added 8.56%	515,221 $2.31 Million
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $92,095 - $132,411	19,107 Added 4.19%	474,579 $2.47 Million
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $1.88 Million - $2.76 Million	-334,030 Reduced 42.31%	455,472 $3.08 Million
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $4.9 Million - $9.78 Million	440,676 Added 126.33%	789,502 $9.05 Million
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $7.47 Million - $9.21 Million	-399,234 Reduced 53.37%	348,826 $7.03 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $13.6 Million - $20.4 Million	748,060 New	748,060 $17 Million
Q2 2022 Aug 15, 2022	SELL	$13.15 - $20.45 $1.23 Million - $1.91 Million	-93,573 Reduced 41.83%	130,115 $2.43 Million
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $2.47 Million - $3.65 Million	-169,983 Reduced 43.18%	223,688 $4.04 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $7.97 Million - $14.2 Million	393,671 New	393,671 $8.17 Million
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $644,345 - $946,824	-24,773 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $8.64 Million - $10.7 Million	-288,422 Reduced 92.09%	24,773 $763,000
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $241,376 - $346,957	-8,255 Reduced 2.57%	313,195 $10.6 Million
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $10.7 Million - $15.3 Million	302,229 Added 1572.39%	321,450 $11.6 Million
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $9.05 Million - $12 Million	-251,505 Reduced 92.9%	19,221 $708,000
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $3.82 Million - $5.75 Million	-84,822 Reduced 23.86%	270,726 $12.2 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $8.68 Million - $17.5 Million	233,895 Added 192.26%	355,548 $25.5 Million
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $5.75 Million - $11.2 Million	-146,161 Reduced 54.58%	121,653 $4.79 Million
Q2 2019 Aug 15, 2019	BUY	$52.76 - $82.19 $12.3 Million - $19.2 Million	234,062 Added 693.48%	267,814 $20.9 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $14.5 Million - $22.5 Million	-273,888 Reduced 89.03%	33,752 $1.42 Million
Q1 2019 May 14, 2019	SELL	$27.39 - $68.41 $12.6 Million - $31.4 Million	-459,458 Reduced 59.9%	307,640 $18.4 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $6.46 Million - $9.61 Million	283,373 Added 58.58%	767,098 $22.1 Million
Q3 2018 Nov 14, 2018	SELL	$29.75 - $43.08 $5.43 Million - $7.86 Million	-182,446 Reduced 27.39%	483,725 $17.6 Million
Q2 2018 Aug 14, 2018	SELL	$21.96 - $39.94 $2.05 Million - $3.73 Million	-93,414 Reduced 12.3%	666,171 $25.2 Million
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $9.2 Million - $14.3 Million	538,031 Added 242.84%	759,585 $17.9 Million
Q4 2017 Feb 14, 2018	SELL	$9.47 - $19.59 $710,382 - $1.47 Million	-75,014 Reduced 25.29%	221,554 $4.34 Million
Q3 2017 Nov 14, 2017	BUY	$7.7 - $9.6 $2.28 Million - $2.85 Million	296,568	296,568 $2.85 Million

Others Institutions Holding QURE

# of Institutions

154

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $333M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account